Trial Profile
Saxenda: Underlying Mechanisms and Clinical Outcomes
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 09 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 09 Aug 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 26 Dec 2022 Results from NCT01562678 NCT02944500 and other study exploring early metabolomic changes in response to liraglutide therapy vs. placebo and in comparison to bariatric surgery, published in the Metabolism - Clinical and Experimental